Valeo Pharma Inc.
VPHIF
$0.0469
-$0.0471-50.11%
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 39.30M | 40.65M | 40.25M | 39.98M | 39.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.30M | 40.65M | 40.25M | 39.98M | 39.85M |
| Cost of Revenue | 31.41M | 32.52M | 31.23M | 30.12M | 29.14M |
| Gross Profit | 7.89M | 8.13M | 9.01M | 9.86M | 10.71M |
| SG&A Expenses | 19.05M | 20.98M | 21.06M | 21.17M | 21.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.46M | 53.50M | 52.30M | 51.30M | 50.50M |
| Operating Income | -11.17M | -12.85M | -12.05M | -11.31M | -10.65M |
| Income Before Tax | -23.64M | -22.03M | -21.06M | -20.60M | -21.68M |
| Income Tax Expenses | -- | -- | -- | -- | -882.10K |
| Earnings from Continuing Operations | -23.64 | -22.03 | -21.06 | -20.60 | -20.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.64M | -22.03M | -21.06M | -20.60M | -20.79M |
| EBIT | -11.17M | -12.85M | -12.05M | -11.31M | -10.65M |
| EBITDA | -9.41M | -11.08M | -10.28M | -9.50M | -9.04M |
| EPS Basic | -0.25 | -0.24 | -0.24 | -0.24 | -0.25 |
| Normalized Basic EPS | -0.14 | -0.15 | -0.14 | -0.14 | -0.15 |
| EPS Diluted | -0.25 | -0.24 | -0.24 | -0.24 | -0.25 |
| Normalized Diluted EPS | -0.14 | -0.15 | -0.14 | -0.14 | -0.15 |
| Average Basic Shares Outstanding | 376.64M | 362.44M | 347.51M | 342.27M | 331.33M |
| Average Diluted Shares Outstanding | 376.64M | 362.44M | 347.51M | 342.27M | 331.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
